The US Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for a single-dose version of Merck & Co.’s Emend (fosaprepitant dimeglumine) for injection, Merck's substance P/neurokinin-1 (NK1) receptor antagonist, in combination with other antiemetic medicines, for the prevention of delayed nausea and vomiting in adults receiving initial and repeat courses of moderately emetogenic chemotherapy (MEC).

Emend for injection is an intravenous prodrug of the oral formulation of Merck’s Emend (aprepitant), which was initially approved in 2003.

The new use for Merck & Co.’s Emend (fosaprepitant dimeglumine) for injection is for a single-dose version.

Source: Merck & Co.